Watch HRTX. Know when insiders buy.
One email the day a filing lands. Free.
HRTX
HERON THERAPEUTICS, INC. /DE/
0.32
+0.00 +0.00%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
60
WATCH · shorts 60
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $60.8MP/E —DIV YIELD —FCF YIELD -19.97%REV TTM —NET INCOME −$34MNET CASH —52W 0.30 – 1.49SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$2M | −$5.5M | — | -0.03 | −$2.2M | $138K | −$2.4M | Aug 10 |
| Q1 2026 · Mar 31 | — | — | — | −$4.8M | −$8.1M | −407.8% | -0.04 | −$1.5M | $391K | −$1.9M | Aug 10 |
| Q4 2025 · Dec 31derived | — | — | — | $38K | −$3M | −180.6% | -0.01 | −$9.2M | $0 | −$9.2M | Feb 26 |
| Q3 2025 · Sep 30 | — | — | — | −$4.1M | −$17.5M | — | -0.10 | $1.3M | $0 | $1.3M | Nov 4 |
| Q2 2025 · Jun 30 | — | — | — | −$1.6M | −$2.4M | — | -0.02 | −$10.9M | $208K | −$11.1M | Aug 10 |
| Q1 2025 · Mar 31 | — | — | — | $3.2M | $2.6M | — | 0.01 | −$8.9M | $109K | −$9M | Aug 10 |
| Q4 2024 · Dec 31derived | — | — | — | $4.2M | $3.7M | — | 0.02 | −$11.8M | $638K | −$12.4M | Feb 26 |
| Q3 2024 · Sep 30 | — | — | — | −$4.5M | −$4.8M | — | -0.03 | $3.4M | $431K | $2.9M | Nov 4 |
| Q2 2024 · Jun 30 | — | — | — | −$6.4M | −$9.2M | — | -0.06 | −$4.6M | — | — | Nov 4 |
| Q1 2024 · Mar 31 | — | — | — | −$4.8M | −$3.2M | — | -0.02 | −$9.5M | — | — | Nov 4 |
| Q4 2023 · Dec 31derived | — | — | — | −$10.2M | −$10.7M | — | -0.05 | $2.5M | $250K | $2.2M | Feb 26 |
| Q3 2023 · Sep 30 | — | — | — | −$24.9M | −$25M | — | -0.17 | −$9.2M | $793K | −$10M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$2.5M | −$20.2M | — | -0.12 | −$27.6M | $317K | −$27.9M | — | — |
| FY2024 · to Dec 31 | — | — | −$11.5M | −$13.6M | — | -0.09 | −$22.5M | $1.7M | −$24.2M | — | — |
| FY2023 · to Dec 31 | — | — | −$110.6M | −$110.6M | — | -0.80 | −$58.8M | $1.5M | −$60.3M | — | — |
| FY2022 · to Dec 31 | — | — | −$174.7M | −$182M | — | -1.67 | −$146.9M | $1.8M | −$148.7M | — | — |
| FY2021 · to Dec 31 | — | — | −$217.8M | −$220.7M | — | -2.24 | −$203.4M | $3M | −$206.4M | — | — |
| FY2020 · to Dec 31 | — | — | −$228.2M | −$227.3M | — | -2.50 | −$184.8M | $6.8M | −$191.6M | — | — |
Every number comes from HERON THERAPEUTICS, INC. /DE/'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.